



Binger Straße 173

D-55216 Ingelheim

Germany

boehringer-ingelheim.de

Project leader



Dr. Ralf Heilker

Lead Identification

Phone +49 7351 54
5590

Fax +49 7351 83
5590

[E-Mail](#)

Co-Project leader



Dr. Mario Beilmann


Nonclinical Drug Safety
88397 Biberach an der
Riss

Phone +49 7351
547726

Fax +49 7351 54
98686

[E-Mail](#)

Project staff




Prof. Bastian Hengerer

CNS Diseases Research

Phone +49 7351 54
4742

Fax +49 7351 83
4742

[E-Mail](#)




Prof. Frank Gillardon

CNS Diseases Research

Phone +49 7351 54
8460

Fax +49 7351 83
8460

[E-Mail](#)



Dr. Tobias Hildebrandt

Target Discovery Research

Phone +49 7351 54
547819

Fax +49 7351 54
547819


[E-Mail](#)

Dr. Florian Meier

Toxicology & Assay
development

Phone +49 7351 54
143219

[E-Mail](#)



Dr. Rolf Göggel
Research Networking
88397 Biberach an der
Riss

Germany

Phone +49 7351 54
96889

Fax +49 7351 54
5997

[E-Mail](#)

Institute presentation

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with high unmet medical need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.

Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit. The company focuses on six major research areas: CardioMetabolic diseases, Central nervous system diseases, Immunology and Inflammation, Infectious diseases, Oncology and Respiratory diseases.

boehringer-ingenelheim.com